Skip to main content
Evidence Snapshot

Acetylcholinesterase

CHEMBL4768 SINGLE PROTEIN Bos taurus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4768
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Acetylcholinesterase as ChEMBL target CHEMBL4768, mapped to UniProt P23795. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Acetylcholinesterase
SINGLE PROTEIN · Bos taurus
As of 2026-09-13
ChEMBL target ID
CHEMBL4768
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23795
Acetylcholinesterase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Acetylcholinesterase matters

As of 2026-09-13

Acetylcholinesterase is reviewed as Acetylcholinesterase (UniProt P23795); the current evidence base includes 16 approved drugs, 681 compounds, and 117 assays, with lead potency reaching pChEMBL 10.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 681 compounds, and 117 assays for this target. The dominant activity type is IC50. CHEMBL225567 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL225567 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Acetylcholinesterase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23795, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

681
Total Compounds
117
Total Assays
16
Approved Drugs
IC50: 616.0, KI: 73.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL225567
 10.7 IC50 —
No preferred name
CHEMBL140476
 10.6 IC50 —
No preferred name
CHEMBL225198
 10.2 IC50 —
No preferred name
CHEMBL338755
 10.2 Ki —
No preferred name
CHEMBL208599
 10.2 IC50 —

Approved Drugs

Structure Compound First Approval
RIVASTIGMINE
CHEMBL636
 1998
DONEPEZIL
CHEMBL502
 1996
DONEPEZIL HYDROCHLORIDE
CHEMBL1678
 1996
TACRINE
CHEMBL95
 1993
TACRINE HYDROCHLORIDE
CHEMBL1677
 1993
AMBENONIUM
CHEMBL1652
 1956
PYRIDOSTIGMINE
CHEMBL1115
 1955
EDROPHONIUM CHLORIDE
CHEMBL1128
 1951
PROCAINAMIDE
CHEMBL640
 1950
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4768